Drug Approval | March 23, 2024
Briefs: Concord Biotech and Neuland Laboratories
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
Eris Lifesciences enters into term loan agreement with Citi Bank
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Subscribe To Our Newsletter & Stay Updated
